Table 4 Comparison of three AKI biomarker study characteristics
| Â | Sapphire [5] | BAKI-I [8] | FINNAKI-CHI3L1 (present study) |
|---|---|---|---|
n | 728 | 181 | 660 |
Biomarker studied | TIMP-2•IGFBP7 | CHI3L1 | CHI3L1 TIMP-2•IGFBP7 |
Centers | Multi | Single | Multi |
Age (years) | 64 (53, 73) | 60 (51, 70) | 64 (53, 73) |
Male gender (%) | 62 | 63 | 62 |
Baseline Cr (ÎĽmol/L) | 80 | 58 | 82 |
Diabetes (%) | 29 | 7.2 | 21.2 |
SAPS II | NA | NA | 38 (29, 49) |
APACHE III | 69 (51, 90) | NA | NA |
SOFA | NA | 9 (7, 11) | 7 (4,9) |
Emergency department | NA | 41.4% | 41.2% |
Medical ICU admission (%) | 31.0 | 59.7 | 70.9 |
AKI stages 2–3 < 12 h (%) | 14.0 | 3.3 | NA |
AKI stages 2–3 < 24 h (%) | NA | 4.9 | 7.4 |
AUC-ROC for AKI stages 2–3 < 12 h | 0.80 | 0.79 | NA |
AUC-ROC for AKI stages 2–3 < 24 h | NA | 0.72 | uCHI3L1, 0.67 NephroCheck, 0.67 |